Culture

Better learners in collared flycatchers are more likely to imitate competitors

image: Female collared flycatcher on the nest.

Image: 
J. Morinay

Many animal species use social information - from conspecifics or other species - to inform their behavioral choices, for example where to look for food or build a nest. In a recent study, ornithologists have shown for the first time that the ability to use such information can depend on an individual's cognitive skills. In the collared flycatcher, females that mastered a learning task faster were more likely to copy the nest site choices of great and blue tits in the same area.

"Our results are exciting because they show for the first time that differences in cognitive abilities between wild-living individuals has consequences for their ability to learn about their habitat and adapt to environmental changes," says Dr Laure Cauchard, a postdoctoral fellow in the School of Biological Sciences at the University of Aberdeen, Scotland, and one of the two lead authors of the study.

Cauchard and colleagues studied nest site choices in the collared flycatcher Ficedula albicollis on Gotland, a northern population isolated from the main population in southeastern Europe. Every year around the middle of August, collared flycatchers migrate due south across the Mediterranean and Sahara to overwinter in southern Africa. They return to Gotland in early April when oak leaves begin to unfold, food for the caterpillars that are the flycatchers' prey. Great and blue tits reside around Gotland year-round and begin their nests several weeks before the flycatchers' return. Previous studies have shown that flycatchers tend to copy the nest site choices of tits, presumably because these reflect the distribution of prey within the habitat.

In an ingenious experiment, the authors first tricked the flycatchers into adopting a spurious behavioral rule of neighboring tits: namely, to only choose nestboxes with a particular geometric symbol. Every spring between 2012 and 2015, the researchers placed an excess of nestboxes - 29 to 106 per forest patch, suitable for both tits and flycatchers - in 12 to 17 (depending on year) different forest patches on Gotland. At the start, either a white circle or triangle was placed at random on each empty nestbox. The tits had no preference for either symbol, which was unrelated to habitat quality. But as soon as a pair of tits nested in a box, the researchers swapped the symbol for its alternative if necessary, so that every nestbox occupied by tits ultimately came to carry the same symbol. As expected from previous research, on their return the flycatchers tended to copy the tits' apparent (but spurious) nest site preference when they chose their own nestbox. The researchers removed the symbol from every box occupied by flycatchers, to ensure that flycatchers copied only the nest site choices of the tits, and not those of other flycatchers.

When the chicks inside a flycatcher nestbox were six days old - that is, when their need for feeding was at its peak - the authors set a problem-solving task for the parents. The nestbox entrance was closed with a door mechanism, beneath which were three perches. The door only opened whenever a parent bringing food sat on the correct perch. Each bird received a learning score, depending on the number of trials before they had mastered the mechanism.

The learning score did not depend on a flycatcher's sex or estimated age. Slow learners scored consistently worse throughout: not only did they need more trips and an overall longer training period to learn to open the mechanism, but they also made more unsuccessful "guesses" (that is, they sat on the wrong perch more often) per trip. But the most interesting result was the relationship between learning score and the likelihood of copying the tits' apparent nest site preference: the worse the learning score of an individual female flycatcher in a pair, the lower the likelihood that the pair had chosen a nestbox with the symbol typical for nestboxes occupied by tits in the same forest patch. This effect was stronger for young female flycatchers than for older females, and absent in male flycatchers.

The researchers conclude that female flycatchers that learn faster are more likely to copy social behavior from other species. But do the results mean that the slowest learners were less intelligent? Not necessarily, caution the authors.

"We should not look on the slow learners as less intelligent, since the slowest learners still used information from tits to make a decision, in this case to reject rather than copy the tits' apparent preference," says Cauchard. "It may be that slow learners processed the social information differently and made their choice based on costs and benefits that we did not quantify here."

The authors plan to replicate their study in other species to see if results are similar. "By repeating these experiments across species that differ in the environmental and social pressures they face, we can unravel the mechanisms that link cognitive abilities and decision-making."

Credit: 
Frontiers

CVIA has just published a new issue, Volume 5 Issue 2

Beijing, 20 November 2020: the journal Cardiovascular Innovations and Applications (CVIA) has just published the second issue of Volume 5. This issue brings together important research from authors in the USA and China.

Papers in the issue are as follows.

REVIEWS

Current Management Strategies in Patients with Heart Failure and Atrial Fibrillation: A Review of the Literature (http://ow.ly/zw3m30rnFaC) by Alex M. Parker, Juan R. Vilaro, Mustafa M. Ahmed and Juan M. Aranda

Epicardial Adipose Tissue in Patients with Obstructive Sleep Apnea: A Systematic Review and Meta-analysis (http://ow.ly/lz9A30rnFbN) by Bin Liu, Yingrui Li, Jianlin Du, Qiang She and Songbai Deng

RESEARCH PAPERS

Comparison of Segmentation Algorithms for Detecting Myocardial Infarction Using Late Gadolinium Enhancement Magnetic Resonance Imaging (http://ow.ly/eGgg30rnOOS) by Yibo Sun, Dongdong Deng, Liping Sun, Yi He, Hui Wang and Jianzeng Dong

WeChat Group of Chest Pain Center for Patients with Acute ST-segment Elevation Myocardial Infarction: Faster Treatment Speed and Better Prognosis (http://ow.ly/qvsK30rnOQm) by Liu Yue, Qin Zhu-Yun, Yang Xin, Tang Rong and Gao Ling-Yun

Comparison of Clinical Value between Right Distal Radial Artery Access and Right Radial Artery Access in Patients Undergoing Coronary Angiography or Percutaneous Coronary Intervention (http://ow.ly/Vsp630rnORC) by Wen Pan, Haixiang Xu, Qingjun Liu and Jianhua Fan

Clinical Analysis of Transcatheter Embolotherapy for Congenital Pulmonary Arteriovenous Fistulas in Children (http://ow.ly/cDPG30rnOSs) by Xue Zhou, Ang Li, Dan Yin, Xu-pei Huang, Jie Tian, Tie-wei Lv, Qi-jian Yi and Ping Xiang

Importance of Mitochondrial-Related Genes in Dilated Cardiomyopathy Based on Bioinformatics Analysis (http://ow.ly/qn8130rnOT2) by Yukuan Chen, Xiaohui Wu, Danchun Hu and Wei Wang

Impact of MitraClip Program on the Volume and Outcomes of Mitral Valve Surgery: A Single-Center Retrospective Study (http://ow.ly/OhOa30rnOTO) by Wei Zhang, Clifton Lewis, Sriniya Mallela, Ali Ebrahimi, Gregory Von Mering and Mustafa Ahmed

CASE REPORT

In-Stent Thrombosis after Antiplatelet Therapy Conversion while Awaiting Coronary Bypass (http://ow.ly/eug030rnOUf) by Nathan Burke, Tawanna Charlton, Hussam Hawamdeh and Ki Park

Credit: 
Compuscript Ltd

'Soft' nanoparticles give plasmons new potential

image: Rice University scientists coupled gold nanoparticles with soft polymers that pull energy from the gold's plasmonic response to light. That energy can then be used to potentially catalyze chemical reactions.

Image: 
Emily Searles/Rice University

HOUSTON - (Dec. 22, 2020) - Bigger is not always better, but here's something that starts small and gets better as it gets bigger.

Just light it up and see.

A team led by Rice University chemists Christy Landes and Stephan Link, both associated with the Smalley-Curl Institute, have made hybrid particles that combine the unbeatable light-harvesting properties of plasmonic nanoparticles with the flexibility of catalytic polymer coatings. Their work could help power long-pursued plasmonic applications in electronics, imaging, sensing and medicine.

Plasmons are the detectable ripples of energy created on the surface of some metals when excited by light or other input. Nanoantennas are microscopic bits of these metals, like gold, silver and aluminum. Because they are sensitive to specific inputs depending on their size, shape and type, they are tunable and therefore useful as sensors, bioimaging agents and even as therapeutics.

The goal of lead authors Emily Searles, a chemistry graduate student, and Sean Collins, a former Carl and Lillian Illig Postdoctoral Fellow at Rice, was to create hybrid nanoantennas with maximum energy transfer from their metal cores to a polymer coating.

They found a way to coat gold nanoparticles on an electrochemical support with a light-sensitive, nickel-based polymer. When triggered by light, energy from the gold's plasmons flows into the coating while the applied potential in the electrochemical cell induces new polymerization from monomers in solution, doubling the coating size. The resulting hybrid damps light scattering from the plasmons by transferring energy into the polymer shell.

"The hope is that because we have put the energy in the polymer, we can now harness that energy to react with other molecules on the surface of the soft interface," Searles said. "There are no reactions included in this paper, but that's where we want to go."

The study appears in the American Chemical Society journal ACS Nano.

The gold-polymer particles studied measured about 35-by-85 nanometers before polymerization and twice that after. At their peak in experiments and simulations, they delivered 50% efficiency in transferring energy from the nanoparticle to the coating, 20% better than the previous benchmark.

Experiments involved putting individual coated particles on an indium tin oxide electrode under a hyperspectral dark-field imaging microscope to record their scattering spectra.

The researchers knew of two possible paths for transferring the light energy between metals and the polymer coating: charge and resonant energy transfer.

"These new hybrids, exploiting energy transfer paths, could solve two current challenges with plasmonic photocatalysis," Link said. "First, efficiencies are often low because charge transfer is slow in comparison to other competing processes.

"Second, charge transfer usually requires a sacrificial counterreaction or the catalyst is poisoned over time," he said. "These energy transfer-based hybrids eliminate the need for a sacrificial reaction because both electron and hole transfer occur simultaneously."

The first challenge was figuring out which polymer was best for getting energy from here to there.

"The nanoantennas and the polymer look very similar if you simply measure the light spectrum they absorb," said Collins, now a lithography process engineer at Intel.

"However, they are actually absorbing the light in completely different ways and the trick is getting those two mechanisms to work together. The nanoantenna casts a huge net to pull light energy in and shares most of the catch to the hungry polymer, giving the polymer far more energy than it could ever harvest alone."

The team determined the plasmonic resonance dipole in the gold and the electric dipole transitions in the nickel polymer aligned when triggered with light, providing a path for charge carriers to migrate from the polymer.

"The energy in the polymer dissipates after a while, but it doesn't appear to return to the gold," Searles said.

The polymer coating does reach a point of diminishing returns, she said. "We found there's a kind of a happy place where you're not going to see any more energy transfer," Searles said. "The polymer you're adding is too far away from the nanoparticle."

All the variables between light input, nanoparticle configuration and polymer will keep Searles busy for years as she researches practical applications.

"The goal is to be able to create a library of these systems," she said. "Depending on the application, we want to shift the spectrum to have the highest energy efficiency. There's a lot of different things to tune, for sure."

Landes emphasized the importance of a collaborative team as well as the ability to combine new imaging and spectroscopy tools to the project.

"If we hope to harness the potential of novel nanomaterials in future applications, it is crucial to understand how such fundamental processes as energy transfer drive their materials properties at the nano- and macroscales," she said. "Such efforts are bigger than can be accomplished by a single method or a single lab."

Credit: 
Rice University

Research news tip sheet: Story ideas From Johns Hopkins Medicine

image: Illustration for Research Story Tips from Johns Hopkins Medicine.

Image: 
Johns Hopkins Medicine

A FIRST LOOK AT HOW THE DRUG SALVINORIN A WORKS IN THE BRAIN

Media Contact: Vanessa McMains, Ph.D., vmcmain1@jhmi.edu

Recent interest in developing therapies from hallucinogenic drugs has scientists exploring how these chemicals work in the brain. Recently, Johns Hopkins Medicine researchers imaged the brains of people who had vaped salvinorin A, a drug used in Native Mexican rituals, and found that, like other psychedelic drugs, it increased the communication across parts of the brain. However, the primary effects of the drug that they observed -- as reported in their paper published Oct. 2, 2020, in Scientific Reports -- suggest that salvinorin A results in more random or disconnected signaling within the default mode network, which is the part of the brain most active when a person is sitting still, relaxing, daydreaming or otherwise not engaged in externally directed mental exercise.

Salvinorin A is a chemical found in the plant Salvia divinorum that produces powerful out-of-body and amnesia-like experiences over a short time frame similar to the effects of nitrous oxide ("laughing gas"), which is used at dental offices.

"Salvinorin A seems to do all the things that researchers believe happen when other psychedelics (such as LSD and psilocybin) act on the brain," says Manoj Doss, Ph.D., postdoctoral research fellow at the Center for Psychedelic and Consciousness Research at the Johns Hopkins University School of Medicine. "The funny thing is that some researchers have selectively focused on the default mode network when that's not even where they find the strongest effects of classic psychedelics. In contrast, that is, in fact, where we found the strongest effects of salvinorin A."

In the study, 12 men vaped salvinorin A crystals and then were scanned by functional magnetic resonance imaging (fMRI) for the next 15 minutes to measure brain activity across networks in the brain. The researchers evaluated the activity within and among eight brain networks: three involved in vision and five others responsible for moving and touch, processing information from the outside world, paying attention, reward evaluation and activating the default mode network when the mind is at rest.

Most of the fMRI-scanned networks seemed to communicate more with one another when influenced by salvinorin A than when the drug was not present, but they communicated less within themselves. The researchers observed particularly decreased synchronization of the default mode network, meaning that the brain's electrical signals became more random and unpredictable.

In future experiments, the research team plans to compare these findings about salvinorin A's impact on the brain with data from imaging done on brains under the influence of other hallucinogenic drugs.

Doss is available for interviews.

SHORT PERIODS OF INTUBATION DURING SURGERY MAY DAMAGE THE LARYNX JUST LIKE LONGER ONES

Media Contact: Brian Waters, bwaters3@jhmi.edu

It's widely known that patients who are intubated for five to six hours during lengthy surgeries are at greater risk for follow-up complications to the larynx (voice box) such as sore throat, difficulty swallowing and hoarseness. Now, Johns Hopkins Medicine researchers have shown that similar problems also may occur in patients intubated for a much shorter period.

In a systematic review of published research on laryngeal injury following intubation, a research team led by Martin Brodsky, Ph.D., Sc.M., associate professor of physical medicine and rehabilitation at the Johns Hopkins University School of Medicine, determined that damage to the larynx can occur with an endotracheal tube in place for as little as one or two hours. Although the injury from short-term intubation is most often mild, it can impact a patient's breathing, swallowing or speaking, requiring separate treatment and more recovery time.

The findings were reported in the Nov. 11, 2020, issue of the journal Anesthesia & Analgesia.

Although the most common complications from intubation are mild, more serious problems can occur. "It is important that both patients and their treating physicians be aware of these possible risks," says Brodsky.

The good news, he says, is that for the majority of patients -- some 80% -- their breathing tubes will be removed after surgery with no injury. The remainder are likely to experience swelling, redness, irritation and abrasions that will generally heal on their own.

Although serious complications such as paralysis and subluxation (dislocation of the cartilage) of the larynx can occur with intubation, they are very rare -- they occur in less than 0.5% of cases.

"Based on the findings from our study, we urge doctors to make sure patients understand that when they are going to be intubated during a surgical procedure -- whether it will be a short or long operation -- there are risks involved from injury to the larynx," says Brodsky. "Being intubated for one to two hours does not eliminate the possibility of long-term damage."

Brodsky adds that better awareness before surgery among doctors and patients about potential intubation-generated laryngeal injury can lead to faster recovery times and improved outcomes.

Brodsky is available for interviews.

CENTRO SOL WORKING TO INCLUDE LATINOS AND UNDERSERVED POPULATIONS IN RESEARCH STUDIES

Media Contact: Waun'Shae Blount, wblount1@jhmi.edu

Despite concerted efforts to remedy an ongoing disparity, research has shown that Latinos and other ethnic minorities have been historically underrepresented in medical research studies, especially clinical trials. Engaging Latinos has been particularly challenging because they often do not have equitable access to vital information that would lead them to participate. Additionally, Latinos often deal with health care providers and study coordinators who don't speak Spanish or are not trained to be culturally competent in working with the Latino community. Other barriers to research participation include poverty, housing instability, lack of transportation, mistrust and competing demands, such as child care and work schedules.

This is where Centro SOL (Center for Salud/Health and Opportunities for Latinos), a Johns Hopkins Medicine research center, is helping to bridge the gap. Since its inception in 2013, Centro SOL's mission has been to improve health care and health education for Latinos in the Baltimore metropolitan region by increasing their involvement in research studies.

"Centro Sol is committed to providing the best quality services for researchers and patients," says Sarah Polk, M.D., Sc.M., Centro Sol team member and assistant professor of pediatrics at the Johns Hopkins University School of Medicine.

According to a recent report in the Journal of Health Care for the Poor and Underserved, Centro SOL consulted from 2014 through 2019 with 77 researchers working for institutions such as The Johns Hopkins University, and its medical school and school of public health; the University of Maryland; the Maryland Institute College of Art; and out-of-state universities. The report documents how Centro SOL helped these investigators increase participation of Baltimore-area Latinos and others who have limited English proficiency in high-quality, culturally competent and ethical research studies by assisting with study planning, reviews of study materials, recruitment of participants and staff members, and translation services.

For example, the report describes how, during the six-year review period, Centro SOL helped researchers build relationships with its target population. Researchers, states the report, were given guidance on proven methods for communicating that help make prospective study recruits feel comfortable and enable them to clearly understand the potential risks and benefits of participating in a research study.

Centro SOL has worked in numerous health care and community settings to promote equity in health and opportunity for Latinos through both research- and community-based programming. Centro SOL has developed close partnerships with key local leaders and organizations, such as Comité Latino de Baltimore, a community group that works to strengthen the region's Latino community, and Gallery Church, which has a predominantly Latino congregation.

Based on feedback from the researchers it has assisted, Centro SOL continues to refine and improve the services it offers.

To learn more about Centro SOL, including its programs and services, go to http://www.jhcentrosol.org.

Polk is available for interviews.

CLEANING UP CELLULAR TRASH HELPS HEARTS RECOVER AFTER HEART ATTACKS

Media Contact: Vanessa McMains, Ph.D., vmcmain1@jhmi.edu

In a new study, Johns Hopkins Medicine researchers have shown how an enzyme can activate and engage a "trash and recycling system" in heart cells to help patients better recover from a heart attack. The researchers say in their study, published Oct. 20, 2020, in Nature Communications, that they believe this system could be modified and used to clean up damaged and misfolded proteins that accumulate in heart cells and eventually become toxic.

The researchers found that the enzyme protein kinase G, which ramps up after a heart attack, influences CHIP (carboxyl terminus of Hsc70-interacting protein) to help move misfolded, damaged proteins to the proteasome, the "recycling plant" of the cell. Based on this finding, the researchers showed that CHIP -- modified by protein kinase G or genetically changed to mimic this modification -- has enhanced ability to clear the damaged proteins. Subsequently, they explain, this prevents progress to heart failure after an attack.

The discovery came when lead author, Mark Ranek, Ph.D., assistant professor of medicine at the Johns Hopkins University School of Medicine, studied mice genetically engineered to block protein kinase G from being turned on after a heart attack. He noticed that CHIP protein levels were much lower than normal, and misfolded/damaged proteins accumulated in greater number in the mouse hearts. This meant that CHIP was a key factor in clearing the damaged proteins. Further supporting the connection was the fact that blocking protein kinase G weakened CHIP's function, while turning on the kinase or using mutations to mimic that it was protective.

"Because CHIP is so small and easy to work with, we think that it will be possible to develop its genetic mutation form into a gene therapy that could be used to treat not only heart disease, but also diseases like Parkinson's or Alzheimer's that also result from the buildup of misfolded proteins, but in this case in the brain," says David Kass, M.D., the Abraham and Virginia Weiss Professor of Cardiology at the Johns Hopkins University School of Medicine.

Kass and his team have applied for a patent related to the development of such a therapy.

Ranek and Kass are available for interviews.

Credit: 
Johns Hopkins Medicine

Promising clinical data for fenofibrate's ability to prevent lung damage in COVID patients

image: Under the microscope.

Image: 
Daniel Hanoch

In what has the potential to significantly change how Corona patients are being treated and the severity of the disease, research spearheaded at Jerusalem's Hebrew University gathered early clinical evidence demonstrating the efficacy of an existing drug in treating COVID-19.

The study was presented at the recent SPARK Conference on Generic Drug Repurposing for COVID-19 by Professor Yaakov Nahmias, Director of the Center for Bioengineering at Hebrew University. Nahmias applied a well-established existing drug to address the buildup of fats in human lung cells caused by the SARS-CoV-2 virus. Initial lab-based results and new data from 1,500 Israel-based Corona patients have been extremely promising and clinical studies are scheduled to begin this week at Barzilai Hospital in Ashkelon, Israel, joining other clinical centers across the United States, South America and Europe.

The study began in July 2020 when Professor Nahmias demonstrated that the SARS-CoV-2 virus was inhibiting the effective breakdown of fat within the lungs. His research then identified the efficacy of Fenofibrate (Tricor), an FDA approved drug that has been on the market since 1975 to address this deficiency in Corona patients. The drug is traditionally designed to address high levels of triglycerides (fats) in the blood. When applied to Corona patients, the study proposes that it will stop the progression of the disease.

"We knew that the system we had developed for Tissue Dynamics provided us with a unique vantage point to understand how the virus operates in the lungs," Professor Nahmias explained. After discovering the efficacy of the drug in the lab-setting, Professor Nahmias, together with Professor Oren Shiboleth of Ichilov Medical Center in Tel Aviv and Dr. Sigal Shafram-Tikva at Hadassah Medical Center in Jerusalem, worked to gather data from 1,500 Corona patients who were on a regiment of drugs designed to reduce the fatty buildup in lung cells.

The results were abundantly clear. Patients who were taking the drugs to speed up the breakdown of fats were recovering from the Corona-caused lung infections in a matter of days. The evidence even showed that there was zero mortality among these patients.

"We showed that the human lungs responded to the SARS-CoV-2 virus by completely changing their metabolism, causing a major buildup of fats in lung cells. Our findings show that this unhealthy fat buildup is a critical factor in COVID-19 patient's deterioration. Patients taking fibrates that work directly to breakdown fats recovered fast from the disease, while those taking medications that build fats like thiazolidinediones, showed greater lung damage and mortality," Professor Nahmias explains.

According to the research team, applying the use of this established drug, which is widely available, inexpensive and has a proven safety record, could alter the effects of COVID-19 from a devastating disease to a far more manageable form of a respiratory cold.

In the coming days, the team will begin an investigator-led Phase 3a clinical study, with financial support from Abbott. Taking place at Barzilai Hospital in Ashkelon, this phase will be led by Professor Shlomo Maayan, Director of the Department of Infectious Diseases.

Other clinical studies intended to corroborate Professor Nahmias's findings are also taking place in the US, Europe and South America. "Even as we see the introduction of numerous vaccines intended to reduce the transmission of the disease and protect vulnerable populations, this drug can help the direct treatment of the virus and reduce its severity and mortality. We hope to see the first results of the clinical phase of this study in the coming months," Professor Maayan said.

Credit: 
The Hebrew University of Jerusalem

The college student in a pandemic

Washington DC, December 22, 2020 - A study in the Journal of the American Academy of Child and Adolescent Psychiatry (JAACAP), published by Elsevier, reports that in a group of first-year university students COVID-19 mitigation protocols, including remote learning and stay-at-home orders had a modest, but persistent, impact on mood and wellness behaviors. Students enrolled in the university's wellness program, however, had improved mood levels and fewer attention problems.

"Like other college and university students, those in our study were displaced from their dorms and peer groups-required to leave campus immediately-and expected to continue their academic work as usual remotely," said lead author William Copeland, PhD, Professor of Psychiatry at the University of Vermont's Larner College of Medicine, Burlington, VT, USA.

Principal investigator and senior author, Jim Hudziak, MD, Professor and Director of Child Psychiatry and the Wellness Environment program at the University of Vermont said: "These data emerged as a consequence of the COVID-19 pandemic from a longitudinal five-year study to test the impact of a novel curricular, residential and digital programs to promote wellbeing and prevent negative outcomes among college students. Our goal was to test the impact of the pandemic on the mood and wellness behaviors in the participants of that study."

The findings are based on surveys conducted during the Spring 2020 semester at the University of Vermont.

As part of a larger study, a sample of 675 first-year university students had already completed a full battery of measures assessing student health and wellbeing at the beginning of the Spring 2020 semester, before the onset of the COVID-19 pandemic. Students in the study also completed nightly surveys on mood and wellness behaviors throughout the spring semester. Of these students, 576 completed the same battery of measures at the end of the spring semester, 600 completed at least one item from a COVID-19-related survey implemented in late March, and 485 completed nightly surveys of mood and wellness behaviors both before (and after) the onset of the COVID-19 crisis.

The pre- and post-battery tests and nightly assessment results were complementary, but not all students had similar experiences. On the battery, students displayed increased levels of both behavior and attention problems from the start of the semester-pre-COVID-19-to the end of the semester. According to Prof. Copeland, the greater the perceived personal disruption by the pandemic, the greater the impact. The researchers also found that students enrolled in UVM's Wellness Environment program had improved mood levels and fewer attention problems compared to the non-Wellness Environment students. On the nightly survey, students reported lower levels of mood and wellness behaviors (e.g., exercise, nutrition, mindfulness, sleep) following the onset of COVID-19. The researchers noted that these changes occurred immediately and persisted across the rest of the spring semester.

First-year college students are believed to be more at risk for several reasons, including the poorly regulated risk-taking and emotional functioning, typical of late adolescent neurodevelopment. The UVM Wellness Environment program, which is designed to support students in the transition to college and encourage students to make healthier decisions, features educational and residential components and has an expectation that students commit to a substance-free environment. The study's authors hypothesized that students in this program may display fewer adverse effects of the COVID-19-related disruptions.

"We suggest that colleges and universities track students' emotional health and develop specific protocols to support mental health for those that struggle. This study also suggests that wellness programs like UVM's may increase social support and support student resilience in the face of ongoing disruptions from college life,"concluded Prof. Copeland.

Credit: 
Elsevier

New imaging method views soil carbon at near-atomic scales

The Earth's soils contain more than three times the amount of carbon than is found in the atmosphere, but the processes that bind carbon in the soil are still not well understood.

Improving such understanding may help researchers develop strategies for sequestering more carbon in soil, thereby keeping it out of the atmosphere where it combines with oxygen and acts as a greenhouse gas.

A new study describes a breakthrough method for imaging the physical and chemical interactions that sequester carbon in soil at near atomic scales, with some surprising results.

The study, "Organo-organic and Organo-mineral Interfaces in Soil at the Nanometer Scale," was published Nov. 30 in Nature Communications.

At that resolution, the researchers showed - for the first time - that soil carbon interacts with both minerals and other forms of carbon from organic materials, such as bacterial cell walls and microbial byproducts. Previous imaging research had only pointed to layered interactions between carbon and minerals in soils.

"If there is an overlooked mechanism that can help us retain more carbon in soils, then that will help our climate," said senior author Johannes Lehmann, the Liberty Hyde Bailey Professor in the School of Integrative Plant Science, Soil and Crop Sciences Section, in the College of Agriculture and Life Sciences. Angela Possinger Ph.D. '19, who was a graduate student in Lehmann's lab and is currently a postdoctoral researcher at Virginia Tech University, is the paper's first author.

Since the resolution of the new technique is near atomic scale, the researchers are not certain what compounds they are looking at, but they suspect the carbon found in soils is likely from metabolites produced by soil microbes and from microbial cell walls. "In all likelihood, this is a microbial graveyard," Lehmann said.

"We had an unexpected finding where we could see interfaces between different forms of carbon and not just between carbon and minerals," Possinger said. "We could start to look at those interfaces and try to understand something about those interactions."

The technique revealed layers of carbon around those organic interfaces. It also showed that nitrogen was an important player for facilitating the chemical interactions between both organic and mineral interfaces, Possinger said.

As a result, farmers may improve soil health and mitigate climate change through carbon sequestration by considering the form of nitrogen in soil amendments, she said.

While pursuing her doctorate, Possinger worked for years with Cornell physicists - including co-authors Lena Kourkoutis, associate professor of applied and engineering physics, and David Muller, the Samuel B. Eckert Professor of Engineering in Applied and Engineering Physics, and the co-director of the Kavli Institute at Cornell for Nanoscale Science - to help develop the multi-step method.

The researchers planned to use powerful electron microscopes to focus electron beams down to sub-atomic scales, but they found the electrons modify and damage loose and complex soil samples. As a result, they had to freeze the samples to around minus 180 degrees Celsius, which reduced the harmful effects from the beams.

"We had to develop a technique that essentially keeps the soil particles frozen throughout the process of making very thin slices to look at these tiny interfaces," Possinger said.

The beams could then be scanned across the sample to produce images of the structure and chemistry of a soil sample and its complex interfaces, Kourkoutis said.

"Our physics colleagues are leading the way globally to improve our ability to look very closely into material properties," Lehmann said. "Without such interdisciplinary collaboration, these breakthroughs are not possible.".

The new cryogenic electron microscopy and spectroscopy technique will allow researchers to probe a whole range of interfaces between soft and hard materials, including those that play roles in the function of batteries, fuel cells and electrolyzers, Kourkoutis said.

Credit: 
Cornell University

COVID immunity lasts up to 8 months, new data reveals

image: Associate Professor Menno van Zelm in his laboratory at Monash University.

Image: 
Monash University

Australian researchers have revealed - for the first time - that people who have been infected with the COVID-19 virus have immune memory to protect against reinfection for at least eight months.

The research is the strongest evidence for the likelihood that vaccines against the virus, SARS-CoV-2, will work for long periods.  Previously, many studies have shown that the first wave of antibodies to coronavirus wane after the first few months, raising concerns that people may lose immunity quickly.  This new work allays these concerns.

The study is the result of a multi-centre collaboration led by Associate Professor Menno van Zelm, from the Monash University Department of Immunology and Pathology,  with the Alfred Research Alliance between Monash University, The Alfred hospital and the Burnet Institute, and published today in the prestigious journal, Science Immunology. The publication reveals the discovery that specific cells within the immune system called memory B cells, "remembers" infection by the virus, and if challenged again, through re-exposure to the virus, triggers a protective immune response through rapid production of protective antibodies.

The researchers recruited a cohort of 25 COVID-19 patients and took 36 blood samples from them from Day 4 post infection to Day 242 post infection.

As with other studies - looking only at the antibody response - the researchers found that antibodies against the virus started to drop off after 20 days post infection.

However - importantly - all patients continued to have memory B cells that recognised one of two components of the SARS-CoV-2 virus, the spike and nucleocapsid proteins. These virus-specific memory B cells were stably present as far as eight months after infection.

According to Associate Professor van Zelm, the results give hope to the efficacy of any vaccine against the virus and also explains why there have been so few examples of genuine reinfection across the millions of those who have tested positive for the virus globally.

"These results are important because they show, definitively, that patients infected with the COVID-19 virus do in fact retain immunity against the virus and the disease," he said.

"This has been a black cloud hanging over the potential protection that could be provided by any COVID-19 vaccine and gives real hope that, once a vaccine or vaccines are developed, they will provide long-term protection."

Credit: 
Monash University

Global study on bird song frequency

image: A global study of songbirds like this field warbler shows that song frequencies primarily depend on body size.

Image: 
Tomáš Albrecht

An analysis of the songs of most of the world's passerine birds reveals that the frequency at which birds sing mostly depends on body size, but is also influenced by sexual selection. The new study from researchers of the Max Planck Institute for Ornithology and colleagues suggests that habitat characteristics do not affect song frequency, thereby refuting a long-standing theory.

Many animals use acoustic signals for communication. These signals have evolved to maximize the effectiveness of the transmission and reception of the sounds, because this helps finding a mate or avoiding predation. One of the fundamental characteristics of acoustic signals is the frequency of the sound. In forested habitats, acoustic signals become attenuated because of sound absorption and scattering from foliage, which is particularly problematic for high-frequency sounds. Hence, a theory from the 1970s predicts that animals living in habitats with dense vegetation emit lower-frequency sounds compared to those living in open areas.

A team of researchers led by Bart Kempenaers from the Max Planck Institute for Ornithology in Seewiesen and Tomáš Albrecht from the Charles University in Praha and the Czech Academy of Sciences analysed the variation in song frequency of more than 5.000 passerine bird species, encompassing 85% of all passerines and half of all avian taxa. PhD student Peter Mikula collected song recordings primarily from xeno-canto, a citizen science repository of bird vocalizations, and from the Macaulay Library of the Cornell Lab of Ornithology.

Relationship between song frequency and body size.

Contrary to the theory, the study reveals that the peak frequency of passerine song does not depend on habitat type. If anything, the data suggest that species living in densely vegetated habitats sing at lower frequencies, which is the opposite of what was predicted. As expected from basic physical principles, the researchers found a strong relationship between song frequency and body size and an effect of shared ancestry. "Both limit the range of sound frequencies an animal can produce", says first author Peter Mikula. Heavier species sing at lower frequencies simply due to the larger vibratory structures of the vocal apparatus.

The study further reveals that species in which males are larger than females produce songs with lower frequencies than expected from their size. "This supports the hypothesis that the frequency of acoustic signals is affected by competition for access to mates", says Bart Kempenaers. Song frequency may act as an indicator of an individual's size and therefore of its dominance or fighting abilities. Thus, song frequency could influence reproductive success through competition with other males or even because it influences male attractiveness to females.

"Our results suggest that the global variation in passerine song frequency is mostly driven by natural and sexual selection causing evolutionary shifts in body size rather than by habitat-related selection on sound propagation", summarizes Tomáš Albrecht.

Credit: 
Max-Planck-Gesellschaft

COVID-19 isolation hurting women more than men

A study by University of Calgary researchers with the Hotchkiss Brain Institute examining sex and gender differences on sleep, empathy and mood during months of isolation due to COVID-19 has found that women are suffering more than men with poorer sleep and more anxiety, depression and trauma, while also feeling more empathetic than men.

The findings published in Frontiers in Global Women's Health is one of the first studies to look at changes in mood and sleep quality during the pandemic. Dr. Veronica Guadagni, PhD, led an online survey of Canadians between March 23 and June 7 of this year. During this time, schools and many businesses were closed, and people stayed home as much as possible as part of a general lock down to prevent transmission of the virus.

The researchers examined data from 573 participants, 112 men and 459 women with a mean age of 25.9 years. More than 66 per cent of the volunteer participants reported poor quality of sleep, more than 39 per cent reported increased symptoms of insomnia, and anxiety and distress were increased in the whole sample. Sleep, depression and anxiety symptoms were more prevalent in women.

"Generally, the study found women reporting more anxiety and depression," says Guadagni, a postdoctoral scholar at the Cumming School of Medicine (CSM). "Their symptoms worsened over time and with greater length of the isolation period. There was a progressive increase in anxiety, depression, poor sleep quality and trauma for males and females. But it was greater for females over time."

The study also found that women reported higher scores on a scale measuring empathy, the ability to understand the emotions of others and to care for others. The greater empathy was, however, associated with greater anxiety, depression and trauma. The authors speculate women's greater concern and anxiety in relation to being caregivers reflects differences in gender roles and norms.

"I was not surprised by the findings; women are the ones who carry the additional load," says Dr. Giuseppe Iaria, PhD, the senior investigator of the study. "Taking care of family and critical situations has always been a huge load on women and females."

When it came to feeling for others, the higher scores for women on the empathy scale may mean they're more likely to follow public health guidelines, such as washing hands, social distancing, and wearing a mask. "If we see that higher empathy is connected to prosocial behaviour we could expect that the people who actually care more for others would be more respectful of the rules. Future studies should test this specific hypothesis," says Guadagni.

The researchers were not able to glean any pre-pandemic sleep or anxiety issues from the participant's data. "We don't know what the interplay between sleep, mental health and empathy was before the isolation for these participants" says Iaria. He hopes the study will "trigger some insights" into the public awareness that some suffer more than others, leading to some acknowledgement and accommodation for women from their partners, employers, and institutions.

The researchers suggest sex and gender differences may play a role in psychological and behavioral reactions to the pandemic. And, they say, these differences need to be considered in planning targeted psychological interventions.

Credit: 
University of Calgary

Mayo Clinic Model of Care and Research leads to favorable outcomes for patients with COVID-19

ROCHESTER, Minn. -- Patients with COVID-19 who received care at Mayo Clinic, whether in the hospital or at home, had outcomes that compared favorably to those reported nationally and internationally. These results demonstrate the value of an integrated, team-based approach to patient care and monitoring, according to a retrospective study of all patients with COVID-19 treated at Mayo Clinic March 1-July 31.

Included in the research during the study period were 7,891 patients who tested positive for COVID-19 and were treated at Mayo Clinic. Of those patients, 897 required hospitalization ? 354 in an ICU. An intensive, multilayered approach was used to manage patient care, leveraging clinical trials and available therapies, and using remote monitoring tools for patients before or after hospital care.

Just over 77.5% of hospitalized patients received at least one COVID-19 therapy, such as an antiviral drug, systemic steroid, immunomodulatory monoclonal antibody or convalescent plasma. Nearly one-quarter of hospitalized patients received two therapies, most commonly a combination of steroids and antiviral medications.

The research, published in Mayo Clinic Proceedings, finds that mortality rates were lower than the national and international averages, and lower than what has been reported in other major studies and expanded-access programs. An overall mortality rate of 1.1% was reported for patients treated at Mayo, with inpatient mortality of 7.1% and ICU mortality of 11.9%.

Watch: Dr. Andrew Badley discusses COVID-19 research

Journalists: Broadcast-quality soundbites with Dr. Badley are in the downloads on the Mayo Clinic News Network. Please "Courtesy: Andrew Badley, M.D./COVID-19 Research Task Force/Mayo Clinic."

"COVID-19 patients treated at Mayo Clinic were diagnosed, monitored and treated with a team- based approach that was designed to ensure that all patients were treated with the most up-to-date, evidence-based, treatments available," says Andrew Badley, M.D., chair of Mayo Clinic's COVID-19 Research Task Force. "By including subject matter experts from a range of disciplines in our treatment teams, and having those treatment teams reviewing the care and progress of each patient daily, our outcomes were better than what had previously been reported."

Most patients who were cared for at Mayo Clinic were not part of the first wave of infections. "Mayo physicians and scientists were able to learn from the experience of other hospitals and adopt the best practices learned into our treatment paradigms," Dr. Badley says. "That knowledge, together with the increased access to experimental agents, is likely the major reason for the outcomes we observed."

Most cases occurred June 1-July 31, accounting for 87.5% of total cases during the study period. Mayo Clinic locations across the Upper Midwest saw 59% of patients with COVID-19, with Mayo Clinic in Arizona seeing 23% and Mayo Clinic in Florida seeing 18%. Of the patients treated, 674 were under 18. Only 13 pediatric patients were admitted to the hospital, and no deaths were reported. Given the low rates of complications, pediatric patients were excluded from subsequent analyses.

Among the 7,217 adults included in the analysis, 87.6% did not require hospitalization. Of these outpatients, 30 died, primarily in hospice or skilled nursing facilities. The median age of adult patients treated at Mayo was 59. There were slightly more male patients than female patients, and male patients were more likely to require hospitalization. The most common comorbidities were chronic obstructive pulmonary disease, 11.8%; diabetes, 9.4%; renal disease, 6.5%; and peripheral vascular disease, 6.2%.

The article notes that COVID-19 mortality rates have declined as the pandemic has progressed, with one possible factor being that testing initially was prioritized for those with specific symptoms and later expanded to asymptomatic people. "The support offered by Mayo Clinic labs to allow us to start aggressive testing was critical to these outcomes," says John O'Horo, M.D., a Mayo Clinic infectious diseases physician and the study's first author. "We were able to stand up drive-thru and hospital testing quickly, identify COVID-19 patients earlier, and initiate care in a more timely manner than would have otherwise been possible."

Another factor contributing to these favorable outcomes was Mayo Clinic's outpatient COVID-19 management teams and its remote monitoring capabilities, says Dr. Badley. These programs allow for high-risk patients to be monitored at home, and detect complications or clinical deterioration early, so that hospital admission and advanced care can be provided in a timely manner. "The high proportion of our patients who were able to participate in these programs was likely a contributor to our outcomes," he says.

Another possible contributor to improved outcomes was the growing acceptance of masks and social distancing, which reduce exposure and potentially reduce the severity of illness.

Mayo Clinic has been a leader in caring for, researching and testing patients with COVID-19 since the pandemic began, with teams developing experimental therapies and clinical trials. Mayo Clinic Laboratories has developed highly accurate diagnostic and antibody tests for COVID-19, and has performed more than 2 million molecular tests for patients. Mayo Clinic was the lead institution for the national Expanded Access Program for Convalescent Plasma, which led to emergency authorization for the use of plasma to help critically ill patients.

As the pandemic continues to surge in many parts of the country, Dr. Badley says the lessons learned by Mayo Clinic and other health care providers in the early phase continue to guide patient care and research going forward.

"The volume of patients that we now are seeing in the Midwest and nationally is vastly greater than it was last spring and summer, but all of the processes that we have put in place and have optimized are continuing," Dr. Badley says. "As this global pandemic approaches its first anniversary, we should be heartened by the advances that have been made in testing, diagnosis and management of COVID-19 and its complications. By adopting best practices learned from all institutions, we can continue to improve outcomes for patients."

Credit: 
Mayo Clinic

New drug inhibits the growth of cancer cells

image: Cartoon representation of the POLRMT-Inhibitor complex.

Image: 
Hauke S. Hillen

A newly developed compound starves cancer cells by attacking their "power plants" - the so-called mitochondria. The new compound prevents the genetic information within mitochondria from being read. Researchers from the Max Planck Institute for Biology of Ageing in Cologne, the Karolinska Institute in Stockholm and the University of Gothenburg report in their study that this compound could be used as a potential anti-tumour drug in the future; not only in mice but also in human patients.

Mitochondria provide our cells with energy and cellular building blocks necessary for normal tissue and organ function. For a long time, the growth of cancer cells was assumed to be independent of mitochondrial function. However, this long-standing dogma has been challenged in recent years. Especially cancer stem cells are highly dependent on mitochondrial metabolism. Due to the central role of mitochondria for normal tissue function, and because drugs that target mitochondrial functions are usually very toxic, it has so far proven difficult to target mitochondria for cancer treatment.

Now an international team of researchers has found a way to overcome these difficulties. "We managed to establish a potential cancer drug that targets mitochondrial function without severe side effects and without harming healthy cells", explains Nina Bonekamp, one of the lead authors of the study. Mitochondria contain their own genetic material, the mitochondrial DNA molecules (mtDNA), whose gene expression is mediated by a dedicated set of proteins. One such protein is the enzyme "mitochondrial RNA polymerase", abbreviated to POLRMT. "Previous findings of our group have shown that rapidly proliferating cells, such as embryonic cells, are very sensitive to inhibition of mtDNA expression, whereas differentiated tissues such as skeletal muscle can tolerate this condition for a surprisingly long time. We reasoned that POLRMT as a key regulator of mtDNA expression might provide a promising target", says Nils-Göran Larsson, head of the research team.

Compound inhibits mitochondrial RNA polymerase

In collaboration with the Lead Discovery Center, a translational drug discovery organization established by Max Planck Innovation, the research team designed a high-throughput test method for identifying a chemical compound that inhibits POLRMT. The POLRMT inhibitor strongly decreased cancer cell viability and tumour growth in tumour-bearing mice, but was generally well tolerated by the animals. "Our data suggest that we basically starve cancer cells into dying without large toxic side effects, at least for a certain amount of time. This provides us with a potential window of opportunity for treatment of cancer", says Nina Bonekamp. "Another advantage of our inhibitor is that we exactly know where it binds to POLRMT and what it does to the protein. This is in contrast to some other drugs that are even in clinical use." With the help of ACUS Laboratories in Cologne and the Max Planck Institute for Biophysical Chemistry in Göttingen, the team identified the chemical binding site of the inhibitor and obtained structural information of the POLRMT-Inhibitor complex.

Bonekamp and Larsson agree that it has been an exciting journey to translate basic findings into a potential drug. They are all the more excited about the possibilities that their findings will open up. "Given the central role of mitochondrial metabolism within the cell, I am sure that our inhibitor of mitochondrial gene expression can be used as a tool in a variety of different areas", explains Bonekamp. "Of course, it is intriguing to further pursue its potential as an anti-cancer drug, but also as a model compound to further understand the cellular effects of mitochondrial dysfunction and mitochondrial diseases."

Credit: 
Max-Planck-Gesellschaft

Study: Bumble bees lacking high-quality habitat have higher pathogen loads

image: Researchers found that bumble bees in landscapes that lacked quality nesting sites and spring flowers for forage had higher levels of pathogens. Their results can inform management practices to support the conservation of bee species that provide essential pollination services, they said.

Image: 
David Cappaert, Bugwood.org

Bumble bees found in low-quality landscapes -- characterized by a relative lack of spring flowers and quality nesting habitat -- had higher levels of disease pathogens, as did bumble bees in areas with higher numbers of managed honey bee hives, according to research led by Penn State scientists.

The results of the study, which examined how a variety of environmental and landscape characteristics influence infectious disease prevalence and bee health, can be used to inform management practices to support the conservation of bee species that provide essential pollination services in natural and agricultural ecosystems, the researchers said.

"Recent worldwide declines in wild and managed bee populations have been attributed to several factors," said the study's lead author, D.J. McNeil, postdoctoral fellow in the Insect Biodiversity Center in Penn State's College of Agricultural Sciences. "For example, extensive habitat loss and degradation has led to a lack of flowers and nest sites, which in turn has contributed to the loss of wild bee abundance and diversity."

He pointed out that more recently, some bee losses -- especially among honey bees and bumble bees -- have been blamed on rising levels of novel bee pathogens, perhaps exacerbated by other factors that weaken bee immunity or resistance.

"Many of the factors known to undermine bee health, such as poor nutrition or exposure to pesticides, can increase susceptibility to disease," McNeil said. "Bees are more likely to be nutritionally deprived in landscapes with fewer and less diverse flowering plants, and poor nutrition can reduce the immune response and increase pathogen and parasite loads."

The incidence and loads of a particular pathogen or parasite in bee populations likely are influenced by the composition of bee communities as well, noted study co-author Heather Hines, associate professor of biology and entomology, Penn State. She explained that the incidence of viruses and parasites in wild bumble bees was higher in the presence of honey bee colonies, which often harbor higher loads of pathogens that are transmissible to native bees.

"Given all these interacting factors, disease prevalence and virulence can be challenging to predict in wild bee populations," Hines said. "Our study is among the first to use data from a large geographic scale to evaluate the relative role of landscape features on the distribution and loads of key pathogens and parasites in wild bees."

To measure pathogen loads, the researchers analyzed specimens of the common eastern bumble bee -- Bombus impatiens, the most abundant bumble bee species in the region. The team collected bumble bee workers from sites across Pennsylvania during peak bumble bee abundance from late June to mid-July in 2018 and 2019. These sites, which included 38 of Pennsylvania's 67 counties, were selected to represent evenly the span of the state and to include a diversity of habitat types and land use patterns.

The researchers then screened for three pathogens known to infect bees -- deformed wing virus, black queen cell virus and Vairimorpha, a microsporidian parasite -- as well as for expression of a gene that regulates immunity. Using statistical analysis techniques, they correlated pathogen presence and loads with several recognized landscape-scale stressors, such as floral abundance, nesting habitat quality, insecticide loading, climatic conditions and interactions with managed honey bees.

Their findings, reported in Scientific Reports, suggested that bumble bees collected within low-quality landscapes exhibited the highest pathogen loads, with spring floral resources and nesting habitat availability serving as the main drivers. The study also found higher loads of bumble bee pathogens where honey bee apiaries are more abundant, as well as a positive relationship between Vairimorpha loads and rainfall, and differences in pathogens by geographic region.

McNeil said results of the study highlight the need to maintain and create high-quality landscapes, such as those with abundant floral and nesting resources, to support healthy wild bee populations. The findings also draw particular focus to the value of spring floral resources, which often are less emphasized in pollinator garden plantings than mid-summer forage.

"Our results suggest that it may be possible to predict potential risks from pathogens and parasites based on these landscape indices, which can help inform decisions as to where habitat restoration and conservation practices should be applied," he said. "This is particularly timely in light of widespread population declines in many insect groups, especially pollinators like bumble bees."

The researchers said they hope to incorporate this information into Beescape, an online tool that allows people across the United States to evaluate their landscape quality. They encourage Pennsylvania homeowners, growers and conservationists to read the Pennsylvania Pollinator Protection Plan, which contains a chapter on best practices for creating forage and habitat for bees in urban, agricultural and natural landscapes.

Credit: 
Penn State

New flower from 100 million years ago brings fresh holiday beauty to 2020

image: Valviloculus pleristaminis.

Image: 
George Poinar Jr., OSU

CORVALLIS, Ore. - Oregon State University researchers have identified a spectacular new genus and species of flower from the mid-Cretaceous period, a male specimen whose sunburst-like reach for the heavens was frozen in time by Burmese amber.

"This isn't quite a Christmas flower but it is a beauty, especially considering it was part of a forest that existed 100 million years ago," said George Poinar Jr., professor emeritus in the OSU College of Science.

Findings were published in the Journal of the Botanical Research Institute of Texas.

"The male flower is tiny, about 2 millimeters across, but it has some 50 stamens arranged like a spiral, with anthers pointing toward the sky," said Poinar, an international expert in using plant and animal life forms preserved in amber to learn more about the biology and ecology of the distant past.

A stamen consists of an anther - the pollen-producing head - and a filament, the stalk that connects the anther to the flower.

"Despite being so small, the detail still remaining is amazing," Poinar said. "Our specimen was probably part of a cluster on the plant that contained many similar flowers, some possibly female."

The new discovery has an egg-shaped, hollow floral cup - the part of the flower from which the stamens emanate; an outer layer consisting of six petal-like components known as tepals; and two-chamber anthers, with pollen sacs that split open via laterally hinged valves.

Poinar and collaborators at OSU and the U.S. Department of Agriculture named the new flower Valviloculus pleristaminis. Valva is the Latin term for the leaf on a folding door, loculus means compartment, plerus refers to many, and staminis reflects the flower's dozens of male sex organs.

The flower became encased in amber on the ancient supercontinent of Gondwana and rafted on a continental plate some 4,000 miles across the ocean from Australia to Southeast Asia, Poinar said.

Geologists have been debating just when this chunk of land - known as the West Burma Block - broke away from Gondwana. Some believe it was 200 million years ago; others claim it was more like 500 million years ago.

Numerous angiosperm flowers have been discovered in Burmese amber, the majority of which have been described by Poinar and a colleague at Oregon State, Kenton Chambers, who also collaborated on this research.

Angiosperms are vascular plants with stems, roots and leaves, with eggs that are fertilized and develop inside the flower.

Since angiosperms only evolved and diversified about 100 million years ago, the West Burma Block could not have broken off from Gondwana before then, Poinar said, which is much later than dates that have been suggested by geologists.

Joining Poinar and Chambers, a botany and plant pathology researcher in the OSU College of Agricultural Sciences, on the paper were Oregon State's Urszula Iwaniec and the USDA's Fernando Vega. Iwaniec is a researcher in the Skeletal Biology Laboratory in the College of Public Health and Human Sciences and Vega works in the Sustainable Perennial Crops Laboratory in Beltsville, Maryland.

Credit: 
Oregon State University

Development of plaques in Alzheimer's disease resolved

A team of researchers from Ruhr-Universität Bochum (RUB) and Vrije Universteit Amsterdam (VU) has determined the development stages of Aβ fibrils and has thus been able to understand the development of plaques. The researchers report in the academic journal Acta Neuropathologica Communications on 11 December 2020.

Joining forces

The team from the Centre for Protein Diagnostics (Prodi) at RUB is working with the Vrije Universiteit Medical Center (VUmc) in order to pool expertise in protein and dementia research. Medical experts such as Baayla Boon from VUmc attends to patients with dementia in the clinic and examines the post mortem brain tissue, which is diligently collected by the Netherlands Brain Bank (NBB). Razor-thin slices are cut from the brain for examination. "Such slices of tissue allow us to look deep within the convolutions of the brain," says Baaylas supervisor Professor Annemieke Rozemuller, Head of Neuropathology at VUmc.

The groups exchange samples and findings at regular meetings. In Bochum, protein researchers led by Professor Klaus Gerwert, Head of Biophysics and Founding Director of Prodi at RUB, examine the brain tissue. The plaques contained in this are illuminated with infrared light in special microscopes. "This allows us to determine the folding of biomarker proteins in the tissue," says Dominik Röhr from Prodi.

A new timeline for plaques

The formation of Aβ fibrils is well known from laboratory experiments. First, Aβ folds like a sheet of paper to form so-called β-sheets. These clump together into small groups, which are known as oligomers. Over time, the β-sheets come together like a deck of cards to form fibrils. The Bochum-based researchers led by Klaus Gerwert utilize this process as an internal clock for plaques. Newly developed plaques contain many oligomers. Over the course of plaque development, fibrils are continuously formed. The researchers thereby concluded that plaques pass through different stages during their development. "It has not been possible to directly observe the development of plaques so far. By combining methods from medicine and physics, new possibilities are now opening up," says Klaus Gerwert, delighted.

On the left is a fully developed plaque of brown-stained Aβ. On the right, the structure of Aβ determined by infrared microscopy is shown. In core are fibrils (red), around are mainly oligomers (blue).

Aβ is the focus in the fight against Alzheimer's disease. A central approach in the search for a cure is dissolving the plaques in the patients' brains. "Early diagnosis of Alzheimer's disease is crucial to prevent Aβ from causing irreparable damage in the brain," says Dominik Röhr. Promising medications are currently undergoing approval testing. These include the antibody aducanumab, which can break down plaques in the brain. The new findings from infrared microscopy indicate that the development of plaques could be stopped at an early stage by preventing the formation of oligomers. These are considered to be particularly harmful to the brain. The toxic effect of Aβ could thus be minimised with suitable drugs.

Credit: 
Ruhr-University Bochum